Olema Pharmaceuticals Inc
For the period ended Mar 31, 2024. Filed May 8, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 8, 2024
OLMA$7.27-1.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity
Condensed Consolidated Statements of Stockholders’ Equity (Unaudited)
(Amounts in thousands, except for share amounts)
| Accumulated | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Additional · Other · Total | |||||||||||
| Common Stock · Paid-in · Comprehensive · Accumulated · Stockholders' | |||||||||||
| Shares · Amount · Capital · (Loss) Income · Deficit · Equity | |||||||||||
| Balances at December 31, 2023 | 54,992,784 | $ | 4 | $ | 559,176 | $ | 347 | (305,632) | $ | 253,895 | |
| Issuance of shares under at-the-market offering, net of issuance costs of $167 | 546,326 | — | 7,901 | — | — | 7,901 | |||||
| Stock-based compensation expense | — | — | 4,704 | — | — | 4,704 | |||||
| Exercise of stock options | 288,402 | — | 940 | — | — | 940 | |||||
| Employee stock purchase plan expense | — | — | 205 | — | — | 205 | |||||
| Vesting of restricted stock awards | 40,351 | — | — | — | — | — | |||||
| Net unrealized loss on marketable securities | — | — | — | (357) | — | (357) | |||||
| Net loss | — | — | — | — | (30,970) | (30,970) | |||||
| Balances at March 31, 2024 | 55,867,863 | $ | 4 | $ | 572,926 | $ | (10) | (336,602) | $ | 236,318 | |
| Accumulated | |||||||||||
| Additional · Other · Total | |||||||||||
| Common Stock · Paid-in · Comprehensive · Accumulated · Stockholders' | |||||||||||
| Shares · Amount · Capital · (Loss) Income · Deficit · Equity | |||||||||||
| Balances at December 31, 2022 | 40,287,097 | $ | 3 | $ | 408,333 | $ | (1,813) | $ | (208,977) | $ | 197,546 |
| Vesting of early exercised stock options | 6,990 | — | 30 | — | — | 30 | |||||
| Vesting of restricted stock awards | 49,318 | — | — | — | — | — | |||||
| Exercise of stock options | 94,915 | — | 220 | — | — | 220 | |||||
| Stock-based compensation expense | — | — | 4,515 | — | — | 4,515 | |||||
| Employee stock purchase plan expense | — | — | 115 | — | — | 115 | |||||
| Net unrealized gain on marketable securities | — | — | — | 835 | — | 835 | |||||
| Net loss | — | — | — | — | (28,286) | (28,286) | |||||
| Balances at March 31, 2023 | 40,438,320 | $ | 3 | $ | 413,213 | $ | (978) | (237,263) | $ | 174,975 | |
Condensed Consolidated Statements of Cash Flows
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.